The preferential cytotoxicity of reovirus for certain transformed cell lines.
about
The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirusDifferential sensitivity of normal and transformed human cells to reovirus infectionOncolytic virus therapy: A new era of cancer treatment at dawnClinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activityExploring Reovirus Plasticity for Improving Its Use as Oncolytic VirusPotential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus VariantsDiminished reovirus capsid stability alters disease pathogenesis and littermate transmissionClinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.Activation of p53 by chemotherapeutic agents enhances reovirus oncolysisOncolytic reovirus effectively targets breast cancer stem cells.Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.Oncolytic viruses as therapeutic agents.Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.Attenuated reovirus displays oncolysis with reduced host toxicityCharacterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.Glycan engagement dictates hydrocephalus induction by serotype 1 reovirus.Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activationThe oncolytic effects of reovirus in canine solid tumor cell lines.Replication-selective oncolytic viruses in the treatment of cancer.Naturally occurring reoviruses for human cancer therapy.Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.Oncolytic viruses for cancer therapy II. Cell-internal factors for conditional growth in neoplastic cells.Oncolytic viruses in the treatment of bladder cancerReovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.The sweet spot: defining virus-sialic acid interactions.Reovirus in cancer therapy: an evidence-based reviewReolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infectionReovirus: a targeted therapeutic--progress and potential.Reovirus nonstructural protein sigma1s is required for establishment of viremia and systemic dissemination.Reovirus-based therapy for cancer.REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.Clinical development directions in oncolytic viral therapy.Progress of oncolytic viruses in sarcomas.Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells.African Swine Fever Virus NP868R Capping Enzyme Promotes Reovirus Rescue during Reverse Genetics by Promoting Reovirus Protein Expression, Virion Assembly, and RNA Incorporation into Infectious Virions.Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinomaOncolytic virotherapy for head and neck cancer: current research and future developments.Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts.
P2860
Q24533256-617E3581-C98E-4B12-8D66-95D136FBAB2BQ24633362-4A984142-76F4-4B53-BD4D-9588A95B4386Q26739714-562D7B7F-9C13-461F-9617-96C7FCF61A7CQ26750568-DA374B2E-912E-4C1B-8628-78D9D3FE1D31Q26771799-ED6919CE-7945-4C49-BC6D-2E6513C7EA25Q26775033-D15C7235-913A-43F8-98A4-015D2AC8D513Q27321066-8D54D2C7-17EE-42CC-8195-52769280AD9BQ27690634-93203B74-5429-4CCB-A025-58331E0ED3C7Q28485141-7D1BB8C8-44F2-484E-9B23-7CFCF05EACDBQ33713657-948C2323-7136-4BB9-A38F-79F31B9AD0B6Q33924515-9A0BC0FF-1FED-44B5-8595-CAD6D4F43A2DQ34329548-DADEED68-745F-4462-AC8D-045F1791DE4EQ34393001-698034C1-50AD-4543-8923-CB0482BCF129Q34543808-350EA48C-EA28-402C-B6D3-670D05A0E6ABQ34759406-7D2A849D-A01B-4BA9-A8AF-2663DF152B24Q35172332-D47B11AB-1E37-486C-AC3B-C92619A606F0Q35262964-BB7E67AC-5C64-4DA9-9777-DE1FE007A868Q35774578-D2711434-AD89-42BB-8E54-3DCF15887E8EQ35912403-8201CA88-F7A1-487B-AB60-73F55D24B54BQ36078485-5D5AE950-6FAF-48CC-BB03-7D3F6473558EQ36099082-15769F69-40F3-41F1-9B9D-33AE50527B2CQ36102568-981AC023-AA4F-4213-BD45-533118EC7011Q36147934-79E05997-9366-4A41-A082-E3FEDB906F7BQ36155535-E636E450-0A99-44FF-AAFF-BCEC3EC053AAQ36685206-D5AFFFB5-0D37-47B7-B6CA-177C72FE0DE1Q37031909-40B03064-0263-45B2-80A8-EC394DD55E55Q37062074-2D4988B0-BCAD-42A3-85CE-F7D59126E8A1Q37285576-2A05CDA7-FBBC-4498-B778-F989ADA33954Q37360608-D1F9C713-A418-41E9-8DC8-43F88E00C097Q37414112-B93C3B75-D3A7-4969-9143-D7C61193BB31Q37519640-35B7FD27-CF6B-43AF-AD5B-51F0A29FF038Q37602536-CBBF9A5C-0130-46EB-B47E-FC741F4112D8Q37857659-2D6D1099-A1D5-4375-88DD-BA7E7D9574C8Q37982449-ADD36AA1-D080-42CD-9C4C-87FB212F715AQ38058884-A70F37C6-4A22-4D15-B8C2-711B0F01E4C9Q38229052-F74EE132-F16E-4468-8FC9-AB9B8528A56EQ38712130-752B8956-9275-43FB-9E1C-4EC8878C2A46Q38885144-4F0EB55B-B2F5-46C9-BC97-37BA0CD62377Q38924562-C0E0D2C4-12B5-46DE-B3B8-F904FCA03DC5Q39562583-133BFCE2-BF66-4AB2-B8E4-3746FFC2E384
P2860
The preferential cytotoxicity of reovirus for certain transformed cell lines.
description
1977 nî lūn-bûn
@nan
1977 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1977 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
name
The preferential cytotoxicity of reovirus for certain transformed cell lines.
@ast
The preferential cytotoxicity of reovirus for certain transformed cell lines.
@en
The preferential cytotoxicity of reovirus for certain transformed cell lines.
@nl
type
label
The preferential cytotoxicity of reovirus for certain transformed cell lines.
@ast
The preferential cytotoxicity of reovirus for certain transformed cell lines.
@en
The preferential cytotoxicity of reovirus for certain transformed cell lines.
@nl
prefLabel
The preferential cytotoxicity of reovirus for certain transformed cell lines.
@ast
The preferential cytotoxicity of reovirus for certain transformed cell lines.
@en
The preferential cytotoxicity of reovirus for certain transformed cell lines.
@nl
P2093
P356
P1433
P1476
The preferential cytotoxicity of reovirus for certain transformed cell lines.
@en
P2093
P2888
P304
P356
10.1007/BF01314776
P577
1977-01-01T00:00:00Z
P6179
1031705085